Obseva Logo4 (00000002).jpg
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
June 30, 2021 01:00 ET | ObsEva SA
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo...
Obseva Logo4 (00000002).jpg
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
May 20, 2021 01:00 ET | ObsEva SA
 -PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment- -Results continue...
Obseva Logo4 (00000002).jpg
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
May 04, 2021 01:00 ET | ObsEva SA
  - EDELWEISS 3 trial of Yselty® expected to report topline data as planned in Q4:21-   GENEVA, Switzerland and BOSTON, MA – May 4, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a...
Obseva Logo4 (00000002).jpg
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
April 30, 2021 16:05 ET | ObsEva SA
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
Obseva Logo4 (00000002).jpg
ObsEva Provides Business Outlook for 2021
February 10, 2021 01:00 ET | ObsEva SA
  GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
Obseva Logo4 (00000002).jpg
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
January 11, 2021 01:00 ET | ObsEva SA
  - European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 - Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of...
Obseva Logo4 (00000002).jpg
ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
December 10, 2020 01:00 ET | ObsEva SA
  PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT]) Show...